Eric A. Klein MDChairman, Glickman Urological & Kidney Institute, Cleveland, Ohio
Eric A. Klein, MD, is the Chairman of the Glickman Urological & Kidney Institute and a staff member in the Taussig Cancer Institute at Cleveland Clinic. His clinical interests are cancers of the prostate, testis and kidney. For several years, including the current edition, Dr. Klein is listed in Best Doctors in America.
Board-certified in urology, Dr. Klein is a frequent lecturer and visiting professor at numerous national and international universities. He was the National Medical Study Coordinator for the National Cancer Institute sponsored Selenium and Vitamin E Cancer Prevention Trial (SELECT). Dr. Klein is the editor of Urology and has been the recipient of numerous awards from the American Cancer Society, the University of Pittsburgh School of Medicine, and the Cleveland Clinic.
Dr. Klein received his medical degree from University of Pittsburgh School of Medicine in Pennsylvania. He completed his residency in urology at Cleveland Clinic and a fellowship in urology at the Memorial Sloan Kettering Cancer Center in New York.
Disclosure: Dr. Klein receives, or has the right to receive, royalty payments for inventions or discoveries commercialized through the companies shown below):
Recent Contributions to PracticeUpdate:
- Identification of Men at Risk of Mortality Before Age 75 Years Based on the Presence of a Family History of Prostate or Breast Cancer and a Polygenic Risk Score
- Prognostic Genomic Biomarkers in Patients With Localized Prostate Cancer
- Recommended Definitions of Aggressive Prostate Cancer
- Serial Molecular Profiling of Low-Grade Prostate Cancer to Assess Tumor Upgrading
- Prostate Cancer Risk Associated With Familial and Hereditary Cancer Syndromes
- Radical Prostatectomy or Observation for Clinically Localized Prostate Cancer
- Clinical Utility and Benefit of Decipher Testing in Men Following Prostatectomy
- Urinary Molecular Biomarker Test Impacts Prostate Biopsy Decision-Making
- Association Between Physical Activity and Risk of Prostate Cancer Defined by Clinical Features and TMPRSS2:ERG
- Benefits of Statins + ADT in Advanced Prostate Cancer